Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Abdominal Neoplasms 1

Interventions

pembrolizumab 30Nivolumab 30cabozantinib 20Ipilimumab 15Magnetic Resonance Spectroscopy 14belzutifan 13lenvatinib 11Axitinib 9Specimen Handling 8Sunitinib 7durvalumab 5CTLA-4 Antigen 5tislelizumab 4atezolizumab 4Radiosurgery 4Interleukin-2 4Everolimus 4Biopsy 4Bevacizumab 4pazopanib 3avelumab 3aldesleukin 3Immunoglobulin G 3Disulfides 3palbociclib 2fludarabine 2entinostat 2adavosertib 2Surveys and Questionnaires 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Renal Cell × Cell Count × Clear all
NCT06318871 2026-05-11

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
5 enrolled
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡